EGFR and breast carcinoma: Both anti‐EGFR monoclonal antibodies (like cetuximab and panitumumab) and next‐generation EGFR tyrosine kinase inhibitors (TKIs) have shown promising therapeutic effects in metastasis inhibition in preclinical and clinical studies.[11] Therefore, in this study, we tried to combine the ICD inducer β‐lap with an EGFR inhibitor CUDC101 to enhance antigen exposure and suppress tumor cell invasion for effective breast cancer treatment.